PTCTHealthcare · BiotechnologyThe 14 Wall Street analysts covering PTC Therapeutics, Inc. hold a median 12-month price target of $100 — +51.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores PTC Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PTCT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +51.4% from it.
Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Barclays | Maintains | Overweight | $120 → $122 |
| 13 Aug 2026 | Wells Fargo | Maintains | Overweight | $106 → $109 |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 31 July 2026 | Morgan Stanley | Maintains | Overweight | $93 → $104 |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 31 July 2026 | Wells Fargo | Maintains | Overweight | $93 → $106 |
| 20 July 2026 | Wells Fargo | Maintains | Overweight | $95 → $93 |
| 20 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 16 July 2026 | Cantor Fitzgerald | Maintains | Overweight | $124 → $130 |
| 16 July 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | — |
| 9 June 2026 | Citigroup | Assumes | Buy | $75 → $108 |
| 27 May 2026 | Jefferies | Upgrade | Buy | — |
| 8 May 2026 | RBC Capital | Maintains | Sector Perform | — |
| 8 May 2026 | TD Cowen | Upgrade | Buy | — |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 30 Mar 2026 | Jefferies | Downgrade | Hold | — |
| 23 Feb 2026 | Morgan Stanley | Maintains | Overweight | — |
| 20 Feb 2026 | B of A Securities | Maintains | Buy | — |
| 20 Feb 2026 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PTCT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, PTC Therapeutics, Inc. returned +8.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 62% of US stocks
Cheaper than 23% of US stocks
Cheaper than 99% of US stocks
Cheaper than 7% of US stocks
Higher than 93% of US stocks
Higher than 84% of US stocks
Higher than 98% of US stocks
Higher than 93% of US stocks
Higher than 25% of US stocks
Higher than 5% of US stocks
Higher than 62% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PTC Therapeutics, Inc. has a market value of $5.5B and an enterprise value of $6.3B.
Revenue in the twelve months to 30 June 2026: $1.0B. The latest quarter grew 101.5% year on year.
Net income over the same four quarters: −$38.4M, a −3.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.58.
Free cash flow in the twelve months to 30 June 2026: −$332.6M.
Trailing P/E: 7.5×; forward P/E: 26.4× — the forward figure prices analyst consensus estimates, not reported earnings.
PTC Therapeutics, Inc. employs 991 people — $1.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PTC Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PTC Therapeutics announced that its executives will speak at the Wells Fargo 21st Annual Healthcare Conference in September. The company did not specify further details in the provided text.
Why it matters — PTCT watchers would care because the scheduled conference participation offers management a platform to discuss the company with investors and analysts.
PTC Therapeutics announced it will present 17 abstracts and data at the 2026 SSIEM Annual Symposium showing that Sephience (sepiapterin) provides sustained metabolic control, enables significant diet liberalization, and maintains a favorable safety profile across patient subgroups.
Why it matters — A PTCT watcher would care because the new data strengthens Sephience's clinical profile, showing broad patient benefits and real-world evidence that could support wider adoption and reimbursement prospects.
PTC Therapeutics' valuation may not fully reflect the upside from its lead asset Sephience, which drives rapid revenue growth and accounts for 63% of product revenue while expanding across major global markets. ST-920, a late-stage gene therapy for Fabry disease acquired from Sangamo, could significantly enhance PTC's valuation if approved by the FDA.
Why it matters — A PTCT watcher would care because potential FDA approval of the late-stage ST-920 gene therapy, alongside Sephience's expanding revenue growth, could significantly enhance the company's valuation.
PTC Therapeutics plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction in a $111 million deal. The acquisition would add a potential one-time treatment to the company's rare disease portfolio, leveraging its existing global commercial and regulatory infrastructure.
Why it matters — PTCT watchers would care because this deal could expand the company's rare disease pipeline with a potential one-time gene therapy treatment while capitalizing on its established commercial and regulatory infrastructure.
PTC Therapeutics announced it is expanding its rare disease portfolio by planning to acquire the ST-920 Fabry disease program from Sangamo Therapeutics through a competitive bankruptcy auction. The company described the move as a "unique opportunity."
Why it matters — A PTCT watcher would care because the acquisition would add a Fabry disease program to the company's rare disease pipeline.
The 14 Wall Street analysts covering PTC Therapeutics, Inc. have a median 12-month price target of $100, with estimates ranging from $70 to $130. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering PTC Therapeutics, Inc., 11 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks PTC Therapeutics, Inc. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, PTC Therapeutics, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +51.4% from the last close, and Ticker Nerd's factor model ranks PTC Therapeutics, Inc. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PTC Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PTCT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $70 to $130 over the next 12 months.
PTC Therapeutics, Inc. returned +8.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders.
The most recent item we track (PRNewsWire, 27 Aug 2026): "PTC Therapeutics to Participate in Upcoming Investor Conferences". PTC Therapeutics announced that its executives will speak at the Wells Fargo 21st Annual Healthcare Conference in September. The company did not specify further details in the provided text.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for people living with rare disorders. Its current portfolio includes treatments for conditions such as Duchenne muscular dystrophy, phenylketonuria, and aromatic L-amino acid decarboxylase deficiency, along with other rare neurological and metabolic diseases. The company also works on gene therapy and small-molecule programs designed to address serious unmet medical needs. PTC Therapeutics serves children and adults in the United States and international markets, and its commercial offerings are supported by a research and development pipeline aimed at expanding its rare disease franchise. Headquartered in Warren, New Jersey, PTC Therapeutics plays a specialized role in the biopharmaceutical market by concentrating on niche therapies for complex, underserved patient populations.
CEO Dr. Matthew B. Klein F.A.C.S., M.D., M.S. · 991 employees · United States · https://www.ptcbio.com
